1. ¹Department of Oncology, Chelsea and Westminster Hospital, Fulham Road, London SW10 9NH, UK
2. ²Department of HIV Medicine, Chelsea and Westminster Hospital, London, UK
3. ³St Bartholomew's & Royal London Hospital, London, UK
4. ⁴Rigshospitalet, Copenhagen, Denmark
5. ⁵Guys and St Thomas Hospital, London, UK
6. ⁶Royal Free Hospital, London, UK
7. ⁷Royal Sussex County Hospital, Brighton, UK

Correspondence: Dr M Bower, Department of Oncology, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK; E-mail: m.bower@ic.ac.uk

Received 19 December 2003; Revised 11 February 2004; Accepted 11 February 2004; Published online 30 March 2004.

Abstract

Testicular germ cell tumour (GCT) is not an AIDS-defining illness despite an increased incidence in men with HIV infection. We performed a matched case-control study comparing outcomes in HIV-positive men and the general population with GCT, using three age and stage matched controls for each case. There was no difference in the 5-year GCT-free survival between cases and controls. However, overall survival was significantly decreased in the cases (log rank P=0.03). HIV was responsible for 70% of this mortality. The relapse-free survival for stage I patients treated with orchidectomy and surveillance was not affected by HIV status (log rank P=0.68). There was no difference in disease free survival in patients with metastatic disease (log rank P=0.78). The overall survival has not improved since the introduction of highly active antiretroviral therapy (log rank P=0.4). Thus, HIV-related GCT is not more aggressive than GCT in the general population.